Material Transfer Agreement Committee Visited Equilab International to Monitor Clinical Trial and Sample Analysis Capabilities Progress

In a continued effort to strengthen Indonesia’s clinical trial ecosystem, the Material Transfer Agreement (MTA) Committee of Indonesia's Ministry of Health, led by Chairman Prof. Dr. Muhammad Nasrum Massi, visited PT Equilab International on June, 2025. This engagement reflects the committee's focus on maintaining rigorous standards for data integrity, confidentiality, and human resource development within the context of clinical trials in Indonesia.

In his address, Professor Nasrum highlighted Indonesia's distinct advantage. He stated, “Indonesia is a large country, rich in natural resources, and that certainly extends to our human resources. We are committed to preserving biodiversity while strengthening national capacity through technology transfer. Local analysis of clinical trial samples is a strategic step toward building self-reliant expertise and generating high-quality data. In this way, the MTA committee also committed to improve the approval process including timeline to contribute in increasing the clinical trial ecosystem and also the number of clinical research conducted in Indonesia.”

Ronal Simanjuntak, President Director of PT Equilab International, resonated with Prof. Nasrum's vision, offering his full endorsement for the committee's commitments to elevate Indonesian laboratory proficiencies and MTA process. "Equilab International, a contract research organization (CRO) in Indonesia, extends our gratitude to the MTA Committee for this visit, which underscored their commitment to data integrity, confidentiality, and human resource development in the Indonesia’s clinical trials. Equilab is thankful for the successful MTA approval of eight applications from Equilab International over the past five years. We also appreciate the committee's effort to improve the MTA approval timelines and the commitment to increase the clinical trial ecosystem in Indonesia as the joint commitment from all clinical research stakeholders in Indonesia“, Mr. Ronal explained.

This visit marks a crucial effort in Indonesia's ongoing journey towards greater self-reliance and achieving excellence in clinical research, ultimately involving the nation to actively participate in global trials.